» Authors » Yoko Machida

Yoko Machida

Explore the profile of Yoko Machida including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 656
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi K, Machida Y, Katayama Y, Yokote H, Saito K, Masumura M, et al.
Rinsho Shinkeigaku . 2019 Jan; 59(1):21-26. PMID: 30606993
A 69-year-old man was admitted with neck muscle weakness, symmetric proximal muscle weakness, skin rash and elevated serum creatine kinase levels. Muscle biopsy showed perifascicular necrosis and perimysial alkaline phosphatase...
2.
Hattori Y, Machida Y, Honda M, Takeuchi N, Yoshiike Y, Ohno H, et al.
J Liposome Res . 2016 Jun; 27(4):264-273. PMID: 27345333
Purpose: Previously, we reported that the cationic liposomes composed of a cationic cholesterol derivative, cholesteryl (2-((2-hydroxyethyl)amino)ethyl)carbamate (OH-C-Chol) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (termed LP-C), could deliver small interfering RNAs (siRNAs) with high...
3.
Wong H, Bauer P, Kurosawa M, Goswami A, Washizu C, Machida Y, et al.
Hum Mol Genet . 2008 Jul; 17(20):3223-35. PMID: 18658163
Huntington's disease (HD) is a fatal neurodegenerative disorder. Despite a tremendous effort to develop therapeutic tools in several HD models, there is no effective cure at present. Acidosis has been...
4.
Doi H, Okamura K, Bauer P, Furukawa Y, Shimizu H, Kurosawa M, et al.
J Biol Chem . 2008 Jan; 283(10):6489-500. PMID: 18167354
Formation of intracellular aggregates is the hallmark of polyglutamine (polyQ) diseases. We analyzed the components of purified nuclear polyQ aggregates by mass spectrometry. As a result, we found that the...
5.
Oyama F, Miyazaki H, Sakamoto N, Becquet C, Machida Y, Kaneko K, et al.
J Neurochem . 2006 Jun; 98(2):518-29. PMID: 16805843
Sodium channel beta4 is a very recently identified auxiliary subunit of the voltage-gated sodium channels. To find the primarily affected gene in Huntington's disease (HD) pathogenesis, we profiled HD transgenic...
6.
Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N
Biochem Biophys Res Commun . 2006 Mar; 343(1):190-7. PMID: 16530728
Huntington disease (HD) is a fatal progressive neurodegenerative disorder associated with expansion of a CAG repeat in the first exon of the gene coding the protein huntingtin (htt). Although the...
7.
Kotliarova S, Jana N, Sakamoto N, Kurosawa M, Miyazaki H, Nekooki M, et al.
J Neurochem . 2005 Apr; 93(3):641-53. PMID: 15836623
Huntington disease is caused by polyglutamine (polyQ) expansion in huntingtin. Selective and progressive neuronal loss is observed in the striatum and cerebral cortex in Huntington disease. We have addressed whether...
8.
Tanaka M, Machida Y, Nukina N
J Mol Med (Berl) . 2005 Mar; 83(5):343-52. PMID: 15759103
Polyglutamine diseases, such as Huntington disease (HD) and spinocerebellar ataxia 1 and 3, are autosomal dominant neurodegenerative disorders. They are caused by CAG trinucleotide repeat expansions that are translated into...
9.
Doi H, Mitsui K, Kurosawa M, Machida Y, Kuroiwa Y, Nukina N
FEBS Lett . 2004 Jul; 571(1-3):171-6. PMID: 15280037
Nuclear aggregates of enhanced green fluorescent protein and nuclear localization signal-fused truncated N-terminal huntingtin containing 150 repeats of glutamine residue were purified from ecdysine-inducible mutant neuro2A cell line by sequential...
10.
Tanaka M, Machida Y, Niu S, Ikeda T, Jana N, Doi H, et al.
Nat Med . 2004 Jan; 10(2):148-54. PMID: 14730359
Inhibition of polyglutamine-induced protein aggregation could provide treatment options for polyglutamine diseases such as Huntington disease. Here we showed through in vitro screening studies that various disaccharides can inhibit polyglutamine-mediated...